Whole-Body [¹⁸F]FDG-PET/CT Imaging of Healthy Controls: Test/Retest Data for Systemic, Multi-Organ Analysis

Positron Emission Tomography (PET) with 2-deoxy-2-[¹⁸F]fluoro-D-glucose (FDG) and Computed Tomography (CT) are key tools in oncology diagnostics. However, most PET studies focus on tumour detection. We propose that a holistic assessment of the macroenvironment using FDG-PET could enhance our understanding of systemic treatment interactions and improve patient care. To achieve this, we aim to develop a normative database for FDG-PET based on healthy controls, providing a reference for identifying voxel-level metabolic aberrations in cancer patients. This approach may uncover treatment-related changes beyond cancer diagnostics. 48 healthy controls who underwent dynamic test-retest whole-body PET/CT imaging post [¹⁸F]FDG injection were included in this cohort. Static PET images (57-62 min post-injection) were reconstructed using CT-based attenuation and scatter correction, with iterative reconstruction incorporating resolution recovery and time-of-flight data. Standardized uptake values (SUVs), tissue densities (HU), and volumes for 135 organs were calculated using in-house segmentation software. The dataset, including anonymized PET/CT images and CT-derived segmentations in NIfTI format, supports the creation of a normative FDG-PET database and enables multi-organ analyses using PET/CT imaging.